The Genetic Regulation of ADPRT/PARP-1 in Aging and Cancer Susceptibility
Authors: Kristin L. Lockett1; Isaac V. Snowhite1; Jennifer J. Hu1
Source: Current Pharmacogenomics, Volume 3, Number 1, March 2005 , pp. 9-19(11)
Publisher: Bentham Science Publishers
Abstract:
The ADP-ribosyltransferase (ADPRT) gene encodes the poly(ADP-ribose)polymerase-1 (PARP-1) enzyme, which plays critical roles in DNA-damage signaling and repair, cell death, maintenance of genomic stability, and carcinogenesis. It may also serve as a potential target for cancer therapy. In this review, we evaluate findings from animal model systems and molecular epidemiological studies to demonstrate the potential role of ADPRT/PARP-1 in aging and carcinogenesis. With increasing interest in associating human cancer risk with single nucleotide polymorphisms (SNPs) and/or dysfunction of ADPRT/PARP-1, several important technical challenges will need to be overcome. These challenges include developing specific functional assays, selecting SNPs with potential functional impact, and exploring statistical methods for gene-gene and gene-environmental interactions. Therefore, this review also highlights strategies to evaluate the functional significance of ADPRT/PARP-1 SNPs in human cancer risk assessment. In summary, dysfunction of PARP-1 may play a critical role in abnormal cellular functions; its molecular mechanism in aging and cancer susceptibility is an issue which needs urgently to be elucidated.Keywords: signaling; tumor suppressor genes; nicotinamide adenine dinucleotide; dna repair; necrosis; chromosomal aberrations; cancer; expression; polymorphism; adp-ribosylation
Document Type: Review article
DOI: 10.2174/1570160053175054
Affiliations: 1: Louisiana State University Health Sciences Center, School of Public Health and Stanley S. Scott Cancer Center, 533 Bolivar Street, CSRB-454, New Orleans, Louisiana 70112, USA.

Click here for Page Help